Invivyd Inc (IVVD): Earnings per share for the last twelve months

Corporate company logo of Invivyd, Inc. (IVVD)

Invivyd, Inc. (IVVD) growth is driven by regulatory approvals and the success of monoclonal antibodies for patient protection. The TTM net income per share reflects price action where the value is maintained at -0.37. Development is based on the commercialization of COVID-19 drugs and grants, while the stability of the scientific core is guaranteed by a stock option system and the targeted hiring of FDA experts.

Invivyd, Inc. (IVVD) - Net earnings per share (EPS TTM) from 04/28/2023 to 11/12/2026

Metric breakdowns and analytics for Invivyd Inc (IVVD)

- stock price and consensus target price:
Stock Price Invivyd Corp|IVVD - Analyst Median Target
- stock exchange capitalization data:
Market Value Invivyd|IVVD - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Accounting Value per Share Invivyd, Inc.|IVVD - Book Capitalization|Market Value to Book Value Ratio invivyd.com|IVVD - Company Total Asset Base
- debt obligations and liquidity statistics:
Total Debt to Capital Invivyd, Inc.|IVVD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Invivyd Corp|IVVD - Company Aggregate Debt|Debt to Book Value Invivyd|IVVD - Company Long-Term Debt|Company Short-Term Debts Invivyd, Inc.|Quick Liquidity Indicator invivyd.com
- earnings and valuation multiples indicators:
IVVD - Company Net Income|Future Profit Invivyd, Inc.|IVVD - Market Cap to Earnings|Forward P/E Multiple Invivyd Corp|IVVD - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Invivyd|IVVD - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Invivyd, Inc.|IVVD - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months invivyd.com|IVVD - Earnings per share growth this year|Earnings growth forecast for next year Invivyd, Inc.
Fundamental valuation:invivyd.com - IVVD
Manufactured products of Invivyd Corp

Professional capital evaluates Invivyd, Inc. (IVVD) through the lens of its ability to monetize the adaptability of its antibodies in government sector deals. An analysis of net earnings per share over 12 months allows for the measurement of the actual profit share attributable to each security, which, in the absence of increasing debt, confirms the fundamental stability and defensive qualities of the asset against market downturns.

Competitor analysis for Invivyd, Inc.

Gilead Sciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Cidara Therapeutics Inc CDTX|Novavax (NVAX) - Earnings per share for the last twelve months|CureVac NV - Earnings per share for the trailing year|Net earnings per share for the last 12 months VALN|Net earnings per share (EPS TTM) Vir Corp|Earnings per share for the last twelve months SIGA Technologies, Inc. (SIGA)|Net earnings per share for the last four quarters emergentbiosolutions.com|Net earnings per share (EPS TTM) AVIR (Atea Pharmaceuticals, Inc.)|Net earnings per share for the last four quarters Enanta Pharmaceuticals Inc. (ENTA)|INO - Earnings per share for the last twelve months|HLVX (HilleVax Inc.) - Earnings per share for the last 12 months|KLRS (Kalaris Therapeutics Inc) - Net earnings per share for the last 12 months|DYAI (Dyadic International, Inc.) - Earnings per share for the last twelve months|NNVC (NanoViricides Inc.) - Net earnings per share (EPS TTM)|Talphera Inc (TLPH) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months COCP (Cocrystal)|Earnings per share for the last twelve months TRAW (trawspharma.com)|Dogwood Therapeutics - Net earnings per share for the last 12 months|qualigeninc.com (QLGN) - Net earnings per one share for the last twelve months|AlloVir Bio - Net earnings per share (EPS TTM)|VBIV (VBI Vaccines Inc.) - Earnings per share for the last 12 months|VIRI (virios.com) - Net earnings per share for the last 12 months|Vaxart - Earnings per share for the trailing year